ホーム › 2型糖尿病 › フロリダ州 › Jacksonville
Jacksonville、FLにおける2型糖尿病の臨床試験
Jacksonvilleとその周辺地域（約30マイル以内）の拠点で、2型糖尿病に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
被験者募集中第3相
- Northeast Research Institute, Fleming Island · 17マイル先
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
被験者募集中第3相
- Northeast Research Institute, Jacksonville
- Westside Center for Clinical Research, Jacksonville
- East Coast Institute for Research, LLC - Southside, Jacksonville
- 他2件
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
被験者募集中第3相
- Northeast Research Institute, Jacksonville
- Northeast Research Institute, Fleming Island · 17マイル先
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
被験者募集中健康なボランティア歓迎
- UF Health Jacksonville, Jacksonville
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
被験者募集中第3相
- Research Site, Jacksonville
- Research Site, Jacksonville
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
被験者募集中第3相
- Jacksonville Center for Clinical Research, Jacksonville
- Fleming Island Center for Clinical Research, Fleming Island · 17マイル先
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
被験者募集中第3相
- Research Site, Fleming Island · 17マイル先
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
被験者募集中第3相
- AURORA-2 Clinical Site, Jacksonville
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
被験者募集中第3相
- Research Site, Jacksonville
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
被験者募集中第3相
- Nemours Chld Clnc Jacksonville, Jacksonville
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
被験者募集中第3相
- Research Site, Fleming Island · 17マイル先
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
被験者募集中第3相
- East Coast Institute For Research, Jacksonville
- Jacksonville Ctr for Clin Res, Jacksonville
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
被験者募集中第3相
- Research Site, Jacksonville
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
被験者募集中観察研究
- Research Site, Jacksonville
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
被験者募集中第3相
- Nemours Children's Health, Jacksonville
他の都市における2型糖尿病の試験
- San Antonio, TX37件の研究
- Houston, TX31件の研究
- Orlando, FL24件の研究
- Boston, MA20件の研究
- Miami, FL19件の研究
- Chicago, IL19件の研究
- Dallas, TX19件の研究
- Columbus, OH18件の研究
- Las Vegas, NV18件の研究
- Atlanta, GA17件の研究
- San Diego, CA17件の研究
- Los Angeles, CA16件の研究
Jacksonvilleにおける他の研究
- 乳がん40件の研究
- 非小細胞肺癌39件の研究
- がん（全種類）29件の研究
- 転移性癌28件の研究
- 大腸癌27件の研究
- 前立腺がん26件の研究
- 肥満症25件の研究
- 心不全21件の研究
- 膵臓がん20件の研究
- 過体重19件の研究
- 多発性骨髄腫18件の研究
- 肺がん17件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。